Wall Street brokerages predict that Heat Biologics Inc (NASDAQ:HTBX) will report sales of $1.50 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Heat Biologics’ earnings, with the lowest sales estimate coming in at $1.20 million and the highest estimate coming in at $1.80 million. The company is scheduled to report its next quarterly earnings results on Thursday, February 21st.
On average, analysts expect that Heat Biologics will report full-year sales of $5.22 million for the current fiscal year, with estimates ranging from $4.90 million to $5.54 million. For the next financial year, analysts expect that the business will report sales of $4.95 million, with estimates ranging from $4.80 million to $5.10 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Heat Biologics.
Heat Biologics (NASDAQ:HTBX) last released its earnings results on Thursday, November 15th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.05. Heat Biologics had a negative return on equity of 94.53% and a negative net margin of 331.02%. The firm had revenue of $1.84 million for the quarter, compared to analysts’ expectations of $1.50 million.
Several equities research analysts recently commented on the company. ValuEngine cut Heat Biologics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 25th. HC Wainwright set a $6.00 price objective on Heat Biologics and gave the company a “buy” rating in a research report on Friday, November 16th.
Several institutional investors have recently added to or reduced their stakes in HTBX. Vanguard Group Inc boosted its position in shares of Heat Biologics by 20.6% during the third quarter. Vanguard Group Inc now owns 798,561 shares of the biopharmaceutical company’s stock valued at $1,597,000 after buying an additional 136,256 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Heat Biologics by 20.6% during the third quarter. Vanguard Group Inc. now owns 798,561 shares of the biopharmaceutical company’s stock valued at $1,597,000 after buying an additional 136,256 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Heat Biologics during the fourth quarter valued at $55,000. Finally, Northern Trust Corp purchased a new stake in shares of Heat Biologics during the second quarter valued at $111,000. 4.70% of the stock is currently owned by institutional investors.
Heat Biologics stock opened at $1.44 on Monday. Heat Biologics has a one year low of $0.95 and a one year high of $4.30.
Heat Biologics Company Profile
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Recommended Story: Why do companies engage in swaps?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.